Russell Investments Group
BBIO icon

Russell Investments Group’s BridgeBio Pharma BBIO Stock Holding History

Russell Investments Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.9M Buy
374,292
+22,573
+6% +$1.58M 0.02% 608
2026
Q1 		$26.1M Sell
351,719
-63,437
-15% -$4.6M 0.03% 555
2025
Q4 		$31.8M Buy
415,156
+31,671
+8% +$2.08M 0.03% 480
2025
Q3 		$19.9M Buy
383,485
+99,744
+35% +$4.86M 0.02% 622
2025
Q2 		$12.3M Buy
283,741
+67,037
+31% +$2.44M 0.02% 766
2025
Q1 		$7.49M Buy
216,704
+212,630
+5,219% +$7.17M 0.01% 951
2024
Q4 		$112K Sell
4,074
-860
-17% -$22.2K ﹤0.01% 2664
2024
Q3 		$126K Buy
4,934
+4,410
+842% +$116K ﹤0.01% 2602
2024
Q2 		$13.3K Sell
524
-46,824
-99% -$1.28M ﹤0.01% 3024
2024
Q1 		$1.46M Buy
47,348
+44,788
+1,750% +$1.52M ﹤0.01% 1815
2023
Q4 		$103K Buy
2,560
+2,452
+2,270% +$73.6K ﹤0.01% 2550
2023
Q3 		$2.85K Buy
108
+15
+16% +$426 ﹤0.01% 3222
2023
Q2 		$1.6K Sell
93
-800
-90% -$12K ﹤0.01% 3274
2023
Q1 		$14.8K Sell
893
-116,267
-99% -$1.36M ﹤0.01% 2845
2022
Q4 		$893K Sell
117,160
-206,036
-64% -$1.97M ﹤0.01% 2033
2022
Q3 		$3.21M Buy
323,196
+87,439
+37% +$908K 0.01% 1295
2022
Q2 		$2.14M Buy
235,757
+78,359
+50% +$655K ﹤0.01% 1552
2022
Q1 		$1.6M Buy
157,398
+39,083
+33% +$401K ﹤0.01% 1739
2021
Q4 		$1.97M Sell
118,315
-9,841
-8% -$416K ﹤0.01% 1815
2021
Q3 		$6M Buy
128,156
+5,411
+4% +$290K 0.01% 1144
2021
Q2 		$7.48M Buy
122,745
+91,202
+289% +$5.21M 0.01% 1092
2021
Q1 		$1.94M Sell
31,543
-4,726
-13% -$309K ﹤0.01% 1887
2020
Q4 		$2.58M Sell
36,269
-6,680
-16% -$322K 0.01% 1622
2020
Q3 		$1.61M Buy
42,949
+8,397
+24% +$264K ﹤0.01% 1824
2020
Q2 		$1.13M Buy
+34,552
New +$1.05M ﹤0.01% 1986

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Russell Investments Group's BBIO Position: Q2 2026 in Review

Russell Investments Group increased its BridgeBio Pharma (BBIO) stake by 6.4% in Q2 2026, buying an estimated $1.58M and bringing the position to 374,292 shares worth $27.9M. The position accounts for 0.02% of the portfolio, ranked #608.

Russell Investments Group first reported a position in BBIO in Q2 2020 and has held it in 25 quarters since. The position peaked at $31.8M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Russell Investments Group held 374,292 shares of BridgeBio Pharma worth $27.9M as of Q2 2026.
  • Russell Investments Group bought 22,573 BridgeBio Pharma shares in Q2 2026, an estimated $1.58M.
  • BridgeBio Pharma made up 0.02% of Russell Investments Group's portfolio in Q2 2026, its #608 holding.
  • Russell Investments Group first reported a position in BridgeBio Pharma in Q2 2020 and has held it in 25 quarters since.
  • Russell Investments Group's BridgeBio Pharma position peaked at $31.8M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.